Filter

Refine by Content Type

Refine by News Editorial Type

Refine by Date

—
  • Print
  • Save

Browse

You are looking at 1 - 1 of 1 items for :

  • Refine by Content Type: All x
Clear All Modify Search
Cover FDA approves first new treatment in 20 years to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure
FDA approves first new treatment in 20 years to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure
ASN Staff

The U.S. FDA has now approved INVOKANA® (canagliflozin) as the only type 2 diabetes (T2D) medicine indicated to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.  Approximately 1 in 3 patients with T2D also has DKD, which can ultimately lead to kidney failure. Once patients reach kidney failure, the average 5-year survival is less than 40%, largely due to cardiovascular-associated morbidity and mortality. This is the first new treatment option in nearly 20 years indicated to slow the progression of DKD in these patients.